The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020. REUTERS/Brendan McDermid

REGENERON PHARMACEUTICALS secured United States approval for its rare bone disorder drug, cutting abnormal bone formation by up to 94%. Shares of the drugmaker rose 4% following the regulatory decision.